Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Patrick Yung Chih Wen, M.D.

Co-Author

This page shows the publications co-authored by Patrick Wen and Sandro Santagata.
Connection Strength

1.723
  1. Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol. 2021 Dec 08.
    View in: PubMed
    Score: 0.244
  2. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.202
  3. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
    View in: PubMed
    Score: 0.176
  4. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
    View in: PubMed
    Score: 0.162
  5. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. J Clin Oncol. 2016 Apr 01; 34(10):e87-9.
    View in: PubMed
    Score: 0.146
  6. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78.
    View in: PubMed
    Score: 0.141
  7. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 01; 15(1):330-7.
    View in: PubMed
    Score: 0.099
  8. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 01 05; 24(1):101-113.
    View in: PubMed
    Score: 0.061
  9. Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2022 01 05; 24(1):64-77.
    View in: PubMed
    Score: 0.061
  10. A Molecularly Integrated Grade for Meningioma. Neuro Oncol. 2021 Sep 11.
    View in: PubMed
    Score: 0.060
  11. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
    View in: PubMed
    Score: 0.054
  12. Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.049
  13. Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12(11):e0187908.
    View in: PubMed
    Score: 0.046
  14. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
    View in: PubMed
    Score: 0.039
  15. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96.
    View in: PubMed
    Score: 0.038
  16. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
    View in: PubMed
    Score: 0.038
  17. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
    View in: PubMed
    Score: 0.037
  18. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
    View in: PubMed
    Score: 0.036
  19. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.